{"id":"placebo-to-mirabegron","safety":{"commonSideEffects":[{"rate":"2-3","effect":"Hypertension"},{"rate":"2","effect":"Headache"},{"rate":"2","effect":"Nasopharyngitis"},{"rate":"1-2","effect":"Tachycardia"},{"rate":"1-2","effect":"Urinary tract infection"}]},"_chembl":{"chemblId":"CHEMBL2095212","moleculeType":"Small molecule","molecularWeight":"396.52"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Mirabegron activates beta-3 adrenergic receptors on the smooth muscle of the bladder detrusor, causing relaxation and increasing bladder capacity during the storage phase of the micturition cycle. Unlike anticholinergic agents, it does not block muscarinic receptors, offering a mechanistically distinct approach to treating overactive bladder symptoms.","oneSentence":"Mirabegron is a beta-3 adrenergic receptor agonist that relaxes the detrusor muscle in the bladder to increase urine storage capacity.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:28:47.179Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Overactive bladder with symptoms of urge incontinence, urgency, and urinary frequency"}]},"trialDetails":[{"nctId":"NCT03049462","phase":"PHASE1","title":"The Physiological Responses and Adaptation of Brown Adipose Tissue to Chronic Treatment With Beta3-Adrenergic Receptor Agonists","status":"RECRUITING","sponsor":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","startDate":"2017-03-13","conditions":"Polycystic Ovary Syndrome","enrollment":100},{"nctId":"NCT05362292","phase":"PHASE4","title":"TReating Incontinence for Underlying Mental and Physical Health","status":"RECRUITING","sponsor":"University of California, San Francisco","startDate":"2022-10-04","conditions":"Urinary Incontinence, Urge, Urinary Incontinence, Overactive Bladder","enrollment":270},{"nctId":"NCT04666636","phase":"PHASE2","title":"Mechanisms for Activation of Beige Adipose Tissue in Humans","status":"RECRUITING","sponsor":"Philip Kern","startDate":"2020-12-07","conditions":"PreDiabetes","enrollment":65},{"nctId":"NCT05990387","phase":"PHASE1, PHASE2","title":"MIrabegron and Physiological Function in Cold Environments","status":"COMPLETED","sponsor":"Indiana University","startDate":"2023-07-19","conditions":"Resting Energy Expenditure, Thermogenesis, Brown Adipose Tissue","enrollment":17},{"nctId":"NCT02216214","phase":"PHASE4","title":"Study to Evaluate the Efficacy, Safety, and Tolerability of Mirabegron in Older Adult Subjects With Overactive Bladder (OAB)","status":"COMPLETED","sponsor":"Astellas Pharma Global Development, Inc.","startDate":"2014-10-07","conditions":"Overactive Bladder (OAB)","enrollment":888},{"nctId":"NCT00912964","phase":"PHASE3","title":"A Study to Test the Efficacy and Safety of the Beta-3 Agonist Mirabegron (YM178) in Patients With Symptoms of Overactive Bladder","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2009-04-28","conditions":"Urinary Bladder, Overactive","enrollment":2030},{"nctId":"NCT00662909","phase":"PHASE3","title":"A Study to Assess Efficacy and Safety of the Beta-3 Agonist Mirabegron (YM178) in Patients With Symptoms of Overactive Bladder","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2008-03-28","conditions":"Urinary Bladder, Overactive","enrollment":2149},{"nctId":"NCT00688688","phase":"PHASE3","title":"Study to Test the Long Term Safety and Efficacy of the Beta-3 Agonist Mirabegron (YM178) in Patients With Symptoms of Overactive Bladder","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2008-04-25","conditions":"Urinary Bladder, Overactive","enrollment":2792},{"nctId":"NCT00689104","phase":"PHASE3","title":"Study to Assess the Efficacy and Safety of the Beta-3 Agonist Mirabegron (YM178) in Patients With Symptoms of Overactive Bladder","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2008-04-28","conditions":"Urinary Bladder, Overactive","enrollment":2336},{"nctId":"NCT04641975","phase":"PHASE3","title":"A Study to Evaluate Mirabegron in Pediatric Participants From 5 to Less Than 18 Years of Age With Overactive Bladder (OAB)","status":"TERMINATED","sponsor":"Astellas Pharma Global Development, Inc.","startDate":"2021-03-15","conditions":"Overactive Bladder (OAB), Pharmacokinetics of Mirabegron","enrollment":26},{"nctId":"NCT02656173","phase":"PHASE4","title":"A Phase 4 Study to Evaluate the Efficacy, Safety, and Tolerability of Mirabegron in Male Subjects With Overactive Bladder (OAB) Symptoms, While Taking the Alpha Blocker for Benign Prostatic Hypertrophy (BPH)","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2016-01-25","conditions":"Overactive Bladder","enrollment":568},{"nctId":"NCT02757768","phase":"PHASE4","title":"A Study to Evaluate the Efficacy, Safety, and Tolerability of Mirabegron in Men With OAB Symptoms While Taking Tamsulosin Hydrochloride for Lower Urinary Tract Symptoms (LUTS) Due to Benign Prostatic Hyperplasia (BPH)","status":"COMPLETED","sponsor":"Astellas Pharma Global Development, Inc.","startDate":"2016-06-13","conditions":"Benign Prostatic Hyperplasia, Overactive Bladder","enrollment":715},{"nctId":"NCT01972841","phase":"PHASE3","title":"This Was a Multinational Study Comparing the Efficacy and Safety of Two Medicines , Solifenacin Succinate and Mirabegron Taken Together, or Separately, or a Mock Treatment (Placebo) in Subjects With Symptoms of Overactive Bladder","status":"COMPLETED","sponsor":"Astellas Pharma Europe B.V.","startDate":"2013-11-05","conditions":"Urinary Bladder Overactive, Urinary Bladder Diseases\\Urologic Diseases, Overactive Bladder","enrollment":3527},{"nctId":"NCT01908829","phase":"PHASE3","title":"A Trial Comparing Combination Treatment (Solifenacin Plus Mirabegron) With One Treatment Alone (Solifenacin)","status":"COMPLETED","sponsor":"Astellas Pharma Europe Ltd.","startDate":"2013-07-10","conditions":"Urinary Bladder Diseases, Urinary Bladder Overactive, Urologic Diseases","enrollment":2174},{"nctId":"NCT01604928","phase":"PHASE2","title":"Study to Test the Efficacy and Safety of YM178 in Subjects With Symptoms of Overactive Bladder","status":"COMPLETED","sponsor":"Astellas Pharma Europe B.V.","startDate":"2004-04-05","conditions":"Urinary Bladder, Overactive","enrollment":260},{"nctId":"NCT02045862","phase":"PHASE3","title":"A Multinational Study Comparing the Long-term Efficacy and Safety of Two Medicines, Solifenacin Succinate and Mirabegron Taken Together, or Separately, in Subjects With Symptoms of Overactive Bladder","status":"COMPLETED","sponsor":"Astellas Pharma Europe B.V.","startDate":"2014-03-17","conditions":"Urinary Bladder Overactive, Overactive Bladder, Urgency Incontinence","enrollment":1829},{"nctId":"NCT00966004","phase":"PHASE3","title":"A Study to Evaluate Safety and Efficacy of YM178 in Patients With Overactive Bladder","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2009-07-24","conditions":"Urinary Bladder, Overactive","enrollment":1139},{"nctId":"NCT01340027","phase":"PHASE2","title":"A Study to Evaluate the Efficacy, Safety and Tolerability of Mirabegron and Solifenacin Succinate Alone and in Combination for the Treatment of Overactive Bladder","status":"COMPLETED","sponsor":"Astellas Pharma Europe B.V.","startDate":"2011-03-29","conditions":"Urologic Diseases, Urinary Bladder Diseases, Urological Manifestations","enrollment":1307},{"nctId":"NCT02893553","phase":"PHASE2","title":"The Effects of Normalizing Blood Pressure on Cerebral Blood Flow in Hypotensive Individuals With Spinal Cord Injury","status":"COMPLETED","sponsor":"James J. Peters Veterans Affairs Medical Center","startDate":"2016-12","conditions":"Spinal Cord Injury, Autonomic Dysreflexia, Baroreceptor Integrity","enrollment":21},{"nctId":"NCT03106623","phase":"PHASE2","title":"Study of ONO-8577 in Patients With Overactive Bladder","status":"COMPLETED","sponsor":"Ono Pharmaceutical Co. Ltd","startDate":"2017-04-07","conditions":"Overactive Bladder","enrollment":207},{"nctId":"NCT03817931","phase":"PHASE4","title":"Higher Neural Changes Following Anticholinergic, Beta 3 Agonist, or Placebo in Patients With Overactive Bladder","status":"COMPLETED","sponsor":"Baylor Research Institute","startDate":"2019-08-05","conditions":"Overactive Bladder, Dementia, Lower Urinary Tract Symptoms","enrollment":12},{"nctId":"NCT06123364","phase":"NA","title":"Extracorporeal Magnetic Innervation in Combination With Mirabegron in the Treatment of Overactive Bladder","status":"COMPLETED","sponsor":"Serdinsek Tamara","startDate":"2019-10-14","conditions":"Overactive Bladder, Overactive Bladder Syndrome","enrollment":56},{"nctId":"NCT02086188","phase":"PHASE4","title":"Study of Behavioral Modification Program and Mirabegron to Improve Urinary Urgency in Multiple Sclerosis","status":"COMPLETED","sponsor":"Theodore R. Brown, MD MPH","startDate":"2014-05","conditions":"Multiple Sclerosis","enrollment":28},{"nctId":"NCT04907032","phase":"PHASE4","title":"Posterior Tibial Nerve Stimulation (PTNS) Plus Mirabegron to Treat Refractory OAB Symptoms (PTNS-M Study)","status":"COMPLETED","sponsor":"University of Alabama at Birmingham","startDate":"2021-10-01","conditions":"Overactive Bladder","enrollment":54},{"nctId":"NCT02462837","phase":"PHASE2","title":"Myrbetriq™ (Mirabegron) to Reduce Pain and Discomfort Following Ureteral Stent Placement","status":"TERMINATED","sponsor":"Southern Illinois University","startDate":"2015-05","conditions":"Urinary Bladder, Overactive, Pain, Lower Urinary Tract Symptoms","enrollment":11},{"nctId":"NCT03926754","phase":"PHASE2, PHASE3","title":"Beta 3 Agonist Treatment in Heart Failure-2","status":"COMPLETED","sponsor":"Henning Bundgaard","startDate":"2017-01-23","conditions":"Heart Failure With Reduced Ejection Fraction NYHA Class III-IV","enrollment":56},{"nctId":"NCT02744430","phase":"PHASE2","title":"Mirabegron as Medical Expulsive Therapy (MET) for Ureteral Stones and Ureteral Stent Pain","status":"COMPLETED","sponsor":"Baylor College of Medicine","startDate":"2017-07-22","conditions":"Ureteral Obstruction, Flank Pain","enrollment":33},{"nctId":"NCT02092181","phase":"PHASE4","title":"A Pilot Study of Mirabegron and Behavioral Modification Including Pelvic Floor Exercise for Overactive Bladder in Parkinson's Disease (MAESTRO)","status":"COMPLETED","sponsor":"Daniel Burdick, MD","startDate":"2014-03","conditions":"Parkinsons Disease","enrollment":30},{"nctId":"NCT03411252","phase":"EARLY_PHASE1","title":"Mirabegron in Achalasia: A Clinical and Manometric Proof of Concept Pilot Study","status":"TERMINATED","sponsor":"Thomas Jefferson University","startDate":"2018-02-15","conditions":"Achalasia","enrollment":5},{"nctId":"NCT01876433","phase":"PHASE2","title":"Beta 3 Agonist Treatment in Heart Failure","status":"COMPLETED","sponsor":"Henning Bundgaard","startDate":"2013-09-30","conditions":"Chronic Heart Failure With Reduced Ejection Fraction (HFrEF)","enrollment":70},{"nctId":"NCT02138747","phase":"PHASE4","title":"A Study to Evaluate Tolerability and Participants Preference Between Mirabegron and Tolterodine Extended Release (ER) in Participants With Overactive Bladder (OAB)","status":"COMPLETED","sponsor":"Astellas Pharma Global Development, Inc.","startDate":"2014-07-24","conditions":"Overactive Bladder (OAB)","enrollment":376},{"nctId":"NCT04286152","phase":"PHASE3","title":"Mirabegron And Ureteral Stent-related Pain (MAP) Trial","status":"UNKNOWN","sponsor":"Unity Health Toronto","startDate":"2020-02-03","conditions":"Nephrolithiasis","enrollment":142},{"nctId":"NCT03187795","phase":"PHASE2","title":"Mirabegron and Oxybutynin Safety and Efficacy Trial in Spinal Cord Injury","status":"UNKNOWN","sponsor":"Kessler Foundation","startDate":"2019-04-03","conditions":"Spinal Cord Injuries, Urinary Bladder, Neurogenic","enrollment":62},{"nctId":"NCT03600766","phase":"PHASE2","title":"Mirabegron for Treatment of Erectile Dysfunction in Patients With LUTS Secondry to BPH: A Randomized Study","status":"UNKNOWN","sponsor":"Mansoura University","startDate":"2018-08-01","conditions":"BPH, Erectile Dysfunction, Prostate Hyperplasia","enrollment":50},{"nctId":"NCT01783470","phase":"PHASE2","title":"Effects of b3-Adrenergic Receptor Agonists on Brown Adipose Tissue","status":"COMPLETED","sponsor":"Aaron Cypess","startDate":"2013-02","conditions":"Obesity","enrollment":15},{"nctId":"NCT02436889","phase":"PHASE4","title":"Treatment of Incontinence Without Memory Problems","status":"COMPLETED","sponsor":"University of California, San Francisco","startDate":"2016-02","conditions":"Urge Incontinence, Urinary Incontinence, Urge","enrollment":23},{"nctId":"NCT02044510","phase":"PHASE2, PHASE3","title":"Urodynamic and Clinical Efficacy of Mirabegron for Neurogenic Bladder Patients","status":"TERMINATED","sponsor":"London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's","startDate":"2014-07","conditions":"Urinary Bladder, Neurogenic","enrollment":32},{"nctId":"NCT03412513","phase":"PHASE4","title":"Mirabegron for Treatment of Overactive Bladder Symptoms in Patients With Parkinson's Disease","status":"UNKNOWN","sponsor":"Seoul National University Hospital","startDate":"2017-07-17","conditions":"Overactive Bladder, Parkinson Disease","enrollment":144},{"nctId":"NCT03012113","phase":"PHASE4","title":"Mirabegron and Brown Adipose Tissue","status":"UNKNOWN","sponsor":"Ingrid Jazet","startDate":"2016-06","conditions":"Obesity","enrollment":20},{"nctId":"NCT02775539","phase":"PHASE2","title":"Beta3 Agonist Treatment in Chronic Pulmonary Hypertension Secondary to Heart Failure","status":"UNKNOWN","sponsor":"Fundación Centro Nacional de Investigaciones Cardiovasculares Carlos III","startDate":"2016-06","conditions":"Pulmonary Hypertension, Mirabegron, Heart Failure","enrollment":80},{"nctId":"NCT02361502","phase":"PHASE4","title":"MIrabegron With oveRACtive bLadder Symptoms in mEn","status":"UNKNOWN","sponsor":"Seoul National University Hospital","startDate":"2015-02","conditions":"Overactive Bladder","enrollment":462},{"nctId":"NCT02169713","phase":"PHASE1","title":"Study to Evaluate the Effect of Solifenacin and Mirabegron on the Tamsulosin Hydrochloride (HCl) Concentrations in Blood in Healthy Male Subjects","status":"COMPLETED","sponsor":"Astellas Pharma Europe B.V.","startDate":"2014-05","conditions":"Healthy Subjects, Pharmacokinetics, Drug-Drug Interaction (DDI)","enrollment":20},{"nctId":"NCT00410514","phase":"PHASE2","title":"A Study of Mirabegron (YM178) in Men With Lower Urinary Tract Symptoms (LUTS) and Bladder Outlet Obstruction (BOO)","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2006-12","conditions":"Lower Urinary Tract Symptoms, Bladder Outlet Obstruction","enrollment":200},{"nctId":"NCT01284309","phase":"PHASE1","title":"A Study to Assess Intraocular Pressure and Ocular Safety of the Beta-3 Agonist Mirabegron in Research Subjects","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2010-11","conditions":"Intraocular Pressure","enrollment":321},{"nctId":"NCT01199523","phase":"PHASE1","title":"A Study to Evaluate the Effect of Oral Mirabegron on the Heart in Healthy Males and Females","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2010-05","conditions":"Healthy Subjects","enrollment":352},{"nctId":"NCT01297179","phase":"PHASE1","title":"A Study to Evaluate the Possible Effects of Taking Mirabegron While Taking a Contraceptive Pill","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2008-10","conditions":"Healthy Volunteers, Pharmacokinetics of Mirabegron","enrollment":30},{"nctId":"NCT01284868","phase":"PHASE1","title":"A Study in Healthy Young Men to Look at What Drives the Cardiovascular Effects After Dosing With Mirabegron.","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2009-07","conditions":"Healthy Volunteers, Pharmacodynamics of Mirabegron","enrollment":12},{"nctId":"NCT01478503","phase":"PHASE1","title":"To Evaluate the Blood and Urine Concentration and the Safety and Tolerability of Increasing Repeated Doses of Mirabegron (YM178) OCAS in Healthy Young and Elderly Males and Healthy Young and Elderly Females","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2005-05","conditions":"Pharmacokinetics, Healthy Subjects","enrollment":96}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":162,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Placebo to Mirabegron","genericName":"Placebo to Mirabegron","companyName":"Astellas Pharma Inc","companyId":"astellas","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Mirabegron is a beta-3 adrenergic receptor agonist that relaxes the detrusor muscle in the bladder to increase urine storage capacity. Used for Overactive bladder with symptoms of urge incontinence, urgency, and urinary frequency.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":2,"withResults":2},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}